STRO stock forecast, quote, news & analysis
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company... Show more
Why Sutro Biopharma (STRO) Stock Is Down -43% in the Last 30 Days
Key Takeaways
- Sutro Biopharma shares fell roughly 43% over the 30 days ending October 30, 2026, sliding from a $16.11 close on September 30 to about $9.10.
- The decline accelerated in mid-October, including a 17.1% single-session drop on October 13 that occurred without a specific company announcement or SEC filing.
- Broader risk-off pressure on small-cap biotech, driven by elevated Treasury yields and a proposed Treasury review of U.S. investment in Chinese biotech, compounded the selling.
- The company is navigating a post-restructuring period focused on its next-generation ADC pipeline after deprioritizing its former lead program, luvelta, in 2025.
- Analyst views remain split: several firms reiterated Buy or Outperform ratings, while independent research services issued downgrades to Sell.
- Investors can explore detailed Price Targets, Earnings data, and Forecast pages for additional context on STRO.
- For automated trading ideas across the market, explore Trending AI Robots.
Sutro Biopharma (STRO) Company Overview and Market Position
Sutro Biopharma, Inc. is a clinical-stage oncology company that designs and develops antibody-drug conjugates (ADCs) and novel biologic formats. The company's technology is built on its XpressCF cell-free protein synthesis platform and its XpressCF+ site-specific conjugation platform, which allow precise control over drug payload placement and ratios. Following a strategic portfolio review completed in March 2025, Sutro restructured its operations—reducing its workforce by roughly two-thirds, exiting internal GMP manufacturing, and shifting to external manufacturing—to concentrate resources on its wholly owned, next-generation ADC programs, beginning with STRO-004, an exatecan ADC targeting Tissue Factor. The company also licenses certain assets, including STRO-003 (a ROR1-targeting ADC) to Ipsen, and its platforms support partners such as Vaxcyte (PCVX). Investors follow STRO primarily for its ADC pipeline, its differentiated conjugation technology, and its cash runway outlook.
Sutro Biopharma (STRO) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, STRO declined approximately 43%, moving from a closing price of $16.11 on September 30, 2026, to about $9.10 by the October 30 close. The selloff was not a single-day event but a persistent grind lower, punctuated by a sharp 17.1% drop on October 13 that pushed shares to $11.01. The stock continued to slide through the rest of the month, reaching levels near its 52-week low of $7.15.
The quarterly trend tells a broader story. Three months earlier, on July 31, 2026, shares closed at $24.17, meaning the stock has fallen roughly 62% over the last quarter. This multi-month de-rating reflects sustained pressure rather than isolated volatility, with the 50-day and 200-day moving averages sitting well above current trading levels and the company's market capitalization compressed to roughly $150 million.
What Drove STRO Stock Price in the Last 30 Days
The 30-day decline was driven less by a single fundamental catalyst than by a combination of positioning, sentiment, and sector-level forces. The most notable single move was the October 13 drop of 17.1%, which occurred without any corresponding company announcement, SEC filing, or reported news—a signal that the move reflected selling pressure rather than a new disclosure.
That pressure intensified alongside a broader risk-off tone in speculative biotech. In late October, small-cap biotech peers slid amid elevated Treasury yields, a technology-led market selloff, and uncertainty around the Treasury's proposed curbs on U.S. investment in Chinese biotech. STRO, with a beta near 1.49 and limited near-term revenue, was particularly exposed to this shift in risk appetite.
Ratings activity also contributed to sentiment. Weiss Ratings downgraded Sutro Biopharma to a "Sell (E+)" designation on October 19. Meanwhile, several sell-side firms remained constructive—H.C. Wainwright reiterated a Buy with a $50 target on October 16, and Wedbush reiterated Outperform with a $60 target on October 15—but these bullish calls did not halt the slide, underscoring the dominance of negative market sentiment during the period.
What Drove STRO Stock Performance Over the Last Quarter
The longer, three-month decline reflects investors re-rating a clinical-stage company in transition. On August 12, Sutro reported second-quarter results that missed expectations: revenue of $9.84 million came in below the roughly $11.96 million consensus estimate and fell 84.57% year over year, while the quarterly loss widened. The revenue decline reflects the winding down of prior collaboration economics following the 2025 restructuring and the deprioritization of the luvelta program.
The restructuring itself remains central to the quarterly narrative. By shifting focus to preclinical, wholly owned assets such as STRO-004, the company has reduced its workforce and exited internal manufacturing—changes that lower costs but also reduce near-term clinical catalysts and revenue visibility. Combined with a cash-intensive development model, these factors have kept the stock under sustained pressure even as several analysts maintain long-term price targets well above the current share price.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's top-performing automated trading bots. While Tickeron offers hundreds of AI trading bots that trade thousands of tickers, only the most relevant and highest-performing bots appear in this section, giving traders a focused view of strategies currently gaining momentum. The bots vary widely in strategy, timeframe, and performance metrics, allowing users to compare approaches that suit different risk profiles and trading styles. For investors tracking volatile names such as STRO, this page can serve as a useful reference for identifying systematic trading signals. Explore the Trending AI Robots section to see which strategies are currently leading the platform.
STRO Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, several factors are likely to shape STRO's trajectory. The company's next quarterly earnings report, estimated for November 9, 2026, will be closely watched for updates on cash runway, collaboration revenue, and any new pipeline milestones. Progress toward an investigational new drug (IND) filing for STRO-227, the company's dual-payload PTK7-targeting ADC, is another key catalyst that analysts have flagged for the second half of 2026.
Beyond company-specific events, investors should monitor broader biotech sentiment, interest-rate movements, and any regulatory developments around cross-border biotech investment, given their recent influence on small-cap valuations. Pipeline data disclosures, partnership activity, and analyst target revisions will also matter. These considerations are informational and are not intended as investment recommendations.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
STRO in +15.33% Uptrend, advancing for three consecutive days on November 09, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where STRO advanced for three days, in 205 of 249 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where STRO's RSI Indicator exited the oversold zone, 43 of 53 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on STRO as a result. In 64 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for STRO just turned positive on November 02, 2026. Looking at past instances where STRO's MACD turned positive, the stock continued to rise in 34 of 45 cases over the following month. The odds of a continued upward trend are 76%.
STRO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STRO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for STRO entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.544) is normal, around the industry mean (3.498). P/E Ratio (-0.554) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (3.982) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. STRO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STRO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of new products in protein vaccines and therapeutics
Industry Biotechnology